The results of a 3-day open-label study of GLP-1 infusion (4 pmol/kg/min) in six patients with HF and T2DM indicated that the therapy was well tolerated and there was a trend toward improved myocardial function [61]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.